Clinical trials: T Cell Subsets

Acute Lymphoblastic Leukemia

Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL

• Completed
• Age: 3 months to 29 years
• Phase 2
• Results posted

This is a phase 2 study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia.

Trial name

NCT03792633

Testing

huCART19

Where

United States

Volunteers

106 people

Sponsor

University of Pennsylvania